Study to Evaluate Effectiveness of Brensocatib for Bronchiectasis
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
Category: Clinical Trials
Clinical Trials
Latest
Study to Evaluate Effectiveness of Brensocatib for Bronchiectasis
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
Read More
Invenio Imaging Completes Enrollment for Ai Lung Cancer Biopsy Study
The multicenter study will evaluate an artificial intelligence module designed for rapid tissue assessment during bronchoscopic procedures.
Read More
Duchenne Muscular Dystrophy Cell Therapy Preserves Heart, Muscle Function
Results from the HOPE-3 trial found that an investigational cell therapy called deramiocel preserved heart and muscle function in boys and young men with Duchenne muscular dystrophy (DMD).
Read More
Experimental Monoclonal Antibody Improved ARDS Outcomes
A proof-of-concept study showed an experimental monoclonal antibody targeting ARDS inflammation increased ventilator-free days and reduced organ failure.
Read More
Twice-yearly COPD Biologic Begins Trial
Windward Bio is evaluating WIN378, a monoclonal antibody designed for twice-yearly dosing in patients with moderate-to-severe COPD.
Read More
Chronic Rhinosinusitis Balloon Begins Trial
A US study is evaluating a drug-coated balloon designed to improve outcomes for chronic rhinosinusitis patients undergoing sinus surgery.
Read More
Microneedle Patch for Peanut Allergies Begins Clinical Trials
A phase 1 study is testing the safety of a microneedle device designed to deliver peanut protein through the skin for desensitization.
Read More
Lung Denervation Trial to Target COPD Phenotype
Nuvaira treated the first patient treated in a clinical trial evaluating a one-time lung denervation therapy for patients with specific COPD symptoms.
Read More
RSV Antiviral Zelicapavir Enters Late-stage Clinical Trials
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Read More
Ai-Generated Drug Rentosertib Trialed for Idiopathic Pulmonary Fibrosis
Insilico Medicine initiated a Phase 3 clinical trial for Rentosertib, an oral medication discovered using artificial intelligence to treat idiopathic pulmonary fibrosis (IPF).
Read More
Positive Data for Inhaled Pulmonary Arterial Hypertension Treatment
Once-daily treprostinil palmitil inhalation powder improved exercise capacity and reduced mortality risk for pulmonary arterial hypertension.
Read More
Positive Ph3 Data for Aspergillosis Antifungal Treatment
Phase 3 trial results indicate a new antifungal medication olorofim is as effective as current standard treatments for invasive aspergillosis with fewer side effects.
Read More
Inhaled Molgramostim Improved Exercise Capacity
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Read More
Nebulized Treprostinil Preserved IPF Lung Function
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Read More
Inhaled Nitric Oxide Therapy Alx1 Well Tolerated in Ph1 Trial
Phase 1 data for the investigational inhaled nitric oxide therapy Alx1 demonstrated the treatment was well tolerated with no serious side effects in healthy volunteers.
Read More
Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function
AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.
Read More
Alpha-1 Drug Candidate Superior to Standard Care
Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Read More
Tezepelumab Reduced Asthma Attacks
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Read More
Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Read More
Enanta Pharma to Present Data for RSV, STAT6 Therapies at ATS 2026
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
New Data on Inhaled Treprostinil for IPF
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Phase 1 Data Incoming for ALX1 iNO Therapy
Phase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
Read More
Phase II Trial for Antiviral Nasal Spray Advances to Next Stage
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
ALA Launches Study to Test Omalizumab for COPD Flare-ups
The COPD-OMA trial will examine if the asthma drug omalizumab (Xolair) benefits COPD patients with sensitivities to indoor allergens.
Read More